Navigation Links
Amarantus Completes Name Change and CUSIP Change
Date:12/3/2012

SUNNYVALE, Calif., Dec. 3, 2012 /PRNewswire/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has completed a name change from Amarantus Biosciences, Inc. to Amarantus Bioscience, Inc. In conjunction with this announcement, the Company has received a new Committee on Uniform Securities Identification Procedures (CUSIP) number of 02300T109. The Company's International Securities Identification Number has also changed to US02300T1097. These changes are part of an ongoing effort to improve the regularity of trading in the Company's common stock. These changes will have no impact on the marketability of the Company's securities, or the ability to trade the common stock through brokerage firms.

The Company believes that its fundamentals remain strong and is looking forward to continuing to update the marketplace regarding developments on an ongoing basis. The Company has not entered into any financing transactions that would cause shareholder dilution since the Company's 10Q was reported on November 19th, 2012. The Company has not sold any shares into the marketplace. None of the officers or directors of the Company have sold any shares into the marketplace. The officers and directors of the corporation continue to believe in the Company and its fundamentals.

About Amarantus Bioscience, Inc.

Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-d
'/>"/>

SOURCE Amarantus Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Secures $1.1 Million in Financing
8. Amarantus BioSciences Issues CEO Letter to Shareholders
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
11. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... N.J. , March 3, 2015  Thingee Corporation, ... will be delivering a presentation entitled, "Technology Adoption: Making ... Thriving through Innovations and Technology ,  in ... March 11 to 13, 2015. Audiences looking to learn ... effectively will want to be in the audience for ...
(Date:3/3/2015)... March 03, 2015 Genedata, a ... discovery and life science research, today announced that ... enterprise platform for use at Pfizer biopharma research ... Genedata is supporting Pfizer’s global deployment and roll ... Centers for Therapeutic Innovation (CTI), and Pharmaceutical Sciences ...
(Date:3/3/2015)... , March 3, 2015  Johnson & Johnson ... South San Francisco (JLABS @SSF), a ... South San Francisco, Calif. The ... up to 50 startups from across the healthcare spectrum ... The first resident startups have been ...
(Date:3/3/2015)... , March 3, 2015  PDL BioPharma, Inc. ... today announced that the third of three shareholder lawsuits ... without prejudice. On February 2, 2015, a ... September on behalf of a putative class of purchasers ... et al., No. 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily dismissed ...
Breaking Biology Technology:Thingee to present at 11th Annual Synergistix Users Conference 2Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2
... a way to wake up the immune system to ... a nanoscale container called a vault directly into lung ... disease growth. The vaults, barrel-shaped nanoscale capsules found ... to slowly release a protein, the chemokine CCL21, into ...
... physical therapists are delighted the members of the California ... importance of Senate Bill 924 and its value to ... Physical Therapy Association, will improve the health care process ... delays and unnecessary costs because they have been unable ...
... Calif., May 3, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... and CEO, will provide an update on the progress of ... company,s business strategy at two investor conferences in the month ... Lynch Health Care Conference at 10:40 am PT (1:40 pm ...
Cached Biology Technology:UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs 2UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs 3UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs 4Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... Boston, MA Tuesday, March 3, 2015 at 11.20 ... Orlando, FL Wednesday, March 4, 2015 ... To access the live webcasts for these events, please visit ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... Feb. 5, 2015  Marken is starting its 35 ... has launched a new marketing campaign to solidify its ... The new campaign focuses on First as ... shipments. The first headline in the series, ... priorities with its client,s priorities. Marken recognizes the need ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... dangers to human health and the environment. North Carolina ... from the U.S. Environmental Protection Agency (EPA) that targets ... overflows every year, and will give urban planners new ... At issue are overflows from "sanitary" sewer systems, ...
... scientists have inventoried an astonishing abundance, diversity and distribution of ... that somehow manage a living in a frigid black world ... Revealed via deep-towed cameras, sonar and other vanguard ... now number 17,650, a diverse collection of species ranging from ...
... b3c newswire / - KINAXO Biotechnologies GmbH ... two new investors in the company, Leifina and Conmit ... Schumacher has been elected as a new member of ... Ullrich, Hellmut Kirchner, Manfred Ferber as well as the ...
Cached Biology News:Lose the fat: Targeting grease to curtail sewer overflows 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
...
Biology Products: